• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[通过考虑疾病进程的预后因素强化慢性髓细胞白血病的治疗]

[The intensification of the therapy of chronic myeloleukemia by taking into account the factors prognostic of the course of the disease].

作者信息

Khoroshko N D

出版信息

Ter Arkh. 1994;66(7):30-5.

PMID:7985125
Abstract

A multifactorial computer analysis of current modalities in relevant treatment performed for 208 patients with chronic myeloid leukemia (CML) has revealed a close relationship between the set of unfavourable factors upon the diagnosis, choice of treatment and the patients' survival. For groups of patients with a standard CML risk it is preferable to use monotherapy. More intensive treatment (polychemotherapy) is indicated in the disease progression. The patients at moderate and high CML risk are recommended to be treated intensively (polychemotherapy, polychemotherapy+leukocytapheresis, splenectomy) from the start, that is upon CML diagnosis. The above approach promotes longer survival of CML patients.

摘要

对208例慢性髓性白血病(CML)患者目前相关治疗方式进行的多因素计算机分析显示,诊断时的不利因素组合、治疗选择与患者生存率之间存在密切关系。对于标准CML风险组的患者,采用单一疗法更为可取。在疾病进展时则需更强化的治疗(联合化疗)。中度和高度CML风险的患者建议从一开始即CML诊断时就进行强化治疗(联合化疗、联合化疗+白细胞去除术、脾切除术)。上述方法可提高CML患者的生存率。

相似文献

1
[The intensification of the therapy of chronic myeloleukemia by taking into account the factors prognostic of the course of the disease].[通过考虑疾病进程的预后因素强化慢性髓细胞白血病的治疗]
Ter Arkh. 1994;66(7):30-5.
2
[The prognostic factors in chronic myeloleukemia].[慢性粒细胞白血病的预后因素]
Ter Arkh. 1993;65(7):23-8.
3
[A modern therapeutic strategy in Ph-positive chronic myeloleukemia].[Ph 阳性慢性髓性白血病的现代治疗策略]
Ter Arkh. 1996;68(7):22-7.
4
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.甲磺酸伊马替尼治疗对采用α-干扰素方案治疗慢性期早期的费城染色体阳性慢性髓性白血病患者预后的影响分析
Cancer. 2003 Oct 1;98(7):1430-7. doi: 10.1002/cncr.11665.
5
Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).异基因干细胞移植后慢性髓性白血病的复发:结局与预后因素:西班牙造血移植组(GETH)慢性髓性白血病小组委员会
Bone Marrow Transplant. 2005 Aug;36(4):301-6. doi: 10.1038/sj.bmt.1705063.
6
[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].[慢性粒细胞白血病的异基因骨髓移植。70例患者的临床结果及危险因素]
Med Clin (Barc). 1995 Nov 11;105(16):605-11.
7
[Chronic myeloid leukemia].[慢性髓系白血病]
Ther Umsch. 1996 Feb;53(2):82-7.
8
Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome.慢性粒细胞白血病的相关供体骨髓移植:预测结局的患者特征
Bone Marrow Transplant. 1996 Apr;17(4):537-42.
9
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.费城染色体阴性、bcr/abl阴性慢性粒细胞白血病患者的特征及预后
Cancer. 2002 Oct 15;95(8):1673-84. doi: 10.1002/cncr.10832.
10
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.年龄对甲磺酸伊马替尼治疗费城染色体阳性慢性粒细胞白血病患者预后的影响。
Cancer. 2003 Sep 15;98(6):1105-13. doi: 10.1002/cncr.11629.